Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors
April 20 2017 - 9:00AM
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy
company advancing novel medicines to address unmet needs in serious
rare and ocular diseases, today announced the appointment of
Richard N. Spivey, Pharm.D., Ph.D. to its board of directors. Dr.
Spivey will be the chairman of the nomination and governance
committee and a member of the audit committee.
“Rich is an executive with over 30 years of experience and has
an impressive track record in drug development and regulatory
approvals,” said Paul Cleveland, executive chairman of the board of
Adverum. “He brings extensive experience and strong
relationships with regulatory agencies, which will be valuable as
we plan and execute our development, regulatory, and commercial
planning strategies. His appointment marks another step forward in
the evolution of Adverum, and I am excited to have him join the
board.”
Dr. Spivey has significant experience in research and
development at leading global pharmaceutical companies. Dr. Spivey
currently serves as a scientific advisor to the pharmaceutical
industry. From 2010 to 2015, Dr. Spivey served as senior vice
president of global regulatory affairs at Allergan, plc. During his
tenure, he was responsible for pharmaceuticals, including the
approvals of Botox and Ozurdex, and medical devices. From 2002 to
2010, Dr. Spivey worked with Meda AB after the acquisition of
MedPointe Pharmaceuticals, serving as chief scientific officer and
head of research and development for both. Earlier in his career,
Dr. Spivey worked for Pharmacia Corporation (now Pfizer, Inc.),
Schering-Plough Corporation (now Merck & Co.),
Parke-Davis/Warner-Lambert (now Pfizer, Inc.), and Boots
Pharmaceuticals, Inc.. Dr. Spivey earned a Ph.D. in Pharmacy
Administration from the University of Minnesota and a Pharm.D. from
the University of Southern California.
Dr. Spivey also serves as a member of the board of directors of
Inotek Pharmaceuticals, where he is chairman of the nominating and
governance committee since 2015.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that
can offer life-changing benefits to patients living with serious
rare and ocular diseases. Adverum has a robust pipeline that
includes product candidates designed to treat wet age-related
macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin
(A1AT) deficiency and hereditary angioedema (HAE). Leveraging
a next-generation adeno-associated virus (AAV)-based directed
evolution platform, the Company generates product candidates
designed to provide durable efficacy by inducing sustained
expression of a therapeutic protein. Adverum has collaboration
agreements with Regeneron Pharmaceuticals to research, develop, and
commercialize gene therapy products for ophthalmic diseases and
Editas Medicine to explore the delivery of genome editing medicines
for the treatment of inherited retinal diseases. Adverum’s core
capabilities include clinical development and in-house
manufacturing expertise, specifically in process development and
assay development. For more information please visit
www.adverum.com.
Forward-looking Statements Statements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, statements regarding Adverum’s
plans, potential opportunities, expectations, projections, goals,
objectives, milestones, strategies and product pipeline, all of
which are based on certain assumptions made by Adverum on current
conditions, expected future developments and other factors Adverum
believes are appropriate in the circumstances. Adverum may not
consummate any plans or product or clinical development goals in a
timely manner, or at all, or otherwise carry out the intentions or
meet the expectations or projections disclosed in its
forward-looking statements, and you should not place undue reliance
on these forward-looking statements. Actual results and the timing
of events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, the risk that
Adverum’s resources will not be sufficient for Adverum to conduct
or continue planned development programs and planned clinical
trials, the risk of a delay in the enrollment of patients in
Adverum’s clinical studies or in the manufacturing of products to
be used in such clinical studies, the risk that Adverum will not be
able to successfully develop or commercialize any of its product
candidates, and the risk that Adverum will fail to receive required
regulatory approvals. Risks and uncertainties facing Adverum are
described more fully in Adverum’s periodic reports filed with the
SEC. All forward-looking statements contained in this press release
speak only as of the date on which they were made. Adverum
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Contacts for Adverum:
Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.
650-665-7222
lpatterson@adverum.com
Jill Steier
Senior Vice President
The Trout Group LLC
646-378-2946
jsteier@troutgroup.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024